NEW YORK, May 14 – Comparative genomics company Exelixis of South San Francisco, Calif., said Monday its first quarter revenues increased 28 percent to $7.7 million as milestone payments rose from collaborations with companies including Bayer, Pharmacia, and Bristol Myers Squibb.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.